Home / Market News / $NNOX
benzinga Corporate Catalyst Impact 55/100 ● neutral

Nanox AI Optimizes Medical Imaging AI For On-Premise Edge Inference With Intel Core Ultra And OpenVINO

Aug 10, 2026, 12:12 PM UTC · Primary ticker $NNOX

Nanox AI, a subsidiary of Nano-X Imaging Ltd., announced the optimization of its medical imaging AI framework for Intel Core Ultra processors using Intel's OpenVINO toolkit. This development enables on-premise edge inference for medical imaging AI applications, potentially improving data security and reducing cloud dependency for healthcare organizations.

Nanox AI has optimized its medical imaging AI application framework to run efficiently on Intel Core Ultra processors using the OpenVINO toolkit. This is significant because it allows healthcare organizations to process AI applications directly on-premise, enhancing data security and reducing reliance on cloud infrastructure. This development is a positive for NNOX as it strengthens their product offering and market position in medical AI. For INTC, it signifies increased adoption of their hardware and software in the specialized healthcare sector. In the short term, this could lead to increased interest in NNOX's solutions. Long-term, it positions both companies to capitalize on the growing demand for secure and efficient AI in healthcare, with the key opportunity being the expansion of on-premise AI deployments.

$NNOX positive Product optimization and partnership
$INTC positive Increased adoption of processors and toolkit
Source: benzinga
Join the waitlist for full signal validation →

Not financial advice. AI-generated analysis for informational purposes only.